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Abstract
Background The patient transition from a hospital to a post-discharge healthcare setting has potential to disrupt continuity 
of medication management and increase the risk of harm. “Connect with Pharmacy” is a new electronic web-based trans-
fer of care initiative employed by Leeds Teaching Hospitals NHS Trust. This allows the sharing of discharge information 
between the hospital and a patient’s chosen community pharmacy. Objective We investigated whether the timely sharing of 
discharge information with community pharmacies via “Connect with Pharmacy” reduced hospital readmission rates in older 
patients. Method To evaluate intervention efficacy, hospital admission data was retrospectively collected. For primary analy-
sis, admission rates were tracked 6-months prior (baseline) and 6-months post-intervention. Secondary measures included 
effect on total length of stay if readmitted, emergency department attendance and duration, and impact of polypharmacy. 
Main outcome measure The rate of non-elective hospital readmissions, 6-months post-intervention. Results In the sample 
(n = 627 patients; Mean age = 81 years), emergency readmission rates following the intervention (M = 1.1, 95% CI [0.98, 
1.22]) reduced by 16.16% relative to baseline (M = 1.31, 95% CI [1.21, 1.42]) (W = 54,725; p < 0.001). There was no reduc-
tion in total length of stay. Subsidiary analysis revealed a post-intervention reduction in number of days spent in hospital 
lasting more than three days (χ2 = 13.37, df = 1, p < 0 .001). There were no statistically reliable differences in the remaining 
secondary measures. Conclusion The results showed a reduction in readmissions and potential post-intervention length of 
stay, indicating there may be further benefits for our older patients’ experiences and hospital flow.
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Impacts on practice
• The sharing of hospital discharge information with com-
munity pharmacies has the potential to reduce readmis-
sion rates in older people.
• Patients who are readmitted for more than 3 days fol-
lowing a timely sharing of hospital discharge informa-
tion may have their stay shortened.
• Further study is needed to ascertain the full benefit of 
sharing hospital discharge information with community 
pharmacies.
Introduction
There is growing evidence that deficiencies in quality of com-
munication exist for patients transitioning between different 
care settings [1]. Information transfer between healthcare pro-
viders to support transitions has traditionally been restricted 
to post, fax or email, often accompanied by telephone calls 
[2–5]. These methods have led to problematic issues such 
as the omission of critical information within referral notes, 
individuals having difficulties reading handwritten discharge 
summaries and a lack of audit trail [2, 4, 6, 7]. Such problems, 
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particularly when they involve medications in the early post-
discharge period, may have substantial implications for 
patient safety [8–10], indeed a study has shown an association 
between discrepancies in discharge medication and readmis-
sion [11].
During hospital stay, nearly every patient will experience at 
least one modification in their medication regimen, and more 
than 75% of patients will have three or more changes [12]. 
Approximately 28–40% of medications are stopped within 
hospital and 45% of medicines prescribed at discharge are new 
[13]. Older people are particularly affected by these modifica-
tions as this population is prone to the complexities of multi-
morbidities and polypharmacy, hence the need for greater 
post-discharge continuity of medication management [3, 14, 
15]. Less than 10% of older patients will be discharged on the 
same medication they were admitted with and unsurprisingly, 
there is a rising level of unmet medication support needs for 
this high-risk population in the community.
Recent research indicates that 37% of older patients experi-
ence medication-related harm within 8 weeks following dis-
charge and the annual financial burden to the UK National 
Health Service (NHS) is estimated to be £396m [8]. Prescrib-
ing errors and adverse drug events appear to increase as a 
function of the number of medications prescribed [16], with 
ten or more medications conveying a higher risk than four to 
nine [7]. Older patients also report a lack of understanding 
about their changed medication regimens which can lead to 
poor adherence, confusion and anxiety [17–19]. These post-
discharge medicines-related problems may be addressed with 
more routine involvement of a community pharmacist [9, 20]. 
A recent systematic review found that when the hospital shared 
discharge information with community pharmacies there was 
a reduction in post-discharge medication discrepancies [20]. 
Other benefits of electronically transferring discharge infor-
mation to and referring patients for support from their com-
munity pharmacies include: (1) quick and secure transfer of 
patient data; (2) reduced rate of readmissions; (3) reduced 
Emergency Department (ED) attendance; (4) shorter length of 
hospital stay for subsequent visits through improved medicines 
reconciliation; (5) reduced post-discharge medication errors 
[21–24]; (6) increased New Medicine Service consultations, 
which have shown to improve medication adherence by 10% 
[25]; and (7) increased post-discharge Medicine Use Reviews. 
These reviews have demonstrated that for every £1 spent by the 
health economy delivering the scheme, £3 of NHS spending 
on ED attendances, hospital admissions and medicines wast-
age is avoided [26].
“Connect with Pharmacy” (CwP) [27] is a new transfer of 
care initiative employed by Leeds Teaching Hospitals NHS 
Trust (LTHT), UK, to address these issues. It uses a secure 
web-based system (PharmOutcomes® provided by Pinna-
cle Health Partnership LLP) that allows timely electronic 
transfer of a patient’s discharge and handover information 
(including referrals for community pharmacy services) 
from the hospital to the patient’s chosen community phar-
macy. The concept is based on a similar model employed 
at Newcastle-upon-Tyne NHS Foundation Trust [24]. CwP 
launched on 16th of January 2017 in collaboration with the 
Local Pharmaceutical Committee, Community Pharmacy 
West Yorkshire. Community Pharmacy West Yorkshire rep-
resents local community pharmacies in the area surrounding 
LTHT and is responsible for advancing the enhanced role of 
community pharmacy. The first phase of the CwP initiative 
focussed on patients using a compliance aid, with a plan to 
roll out the programme to all patients that could benefit from 
a further review by a community pharmacist post-discharge.
Aims of the study
The primary aim of this study was to evaluate whether CwP 
reduced hospital readmission in older patients in the first 
phase of this programme (i.e. patients using a compliance 
aid). The secondary aim of the study was to identify if the 
intervention reduced ED attendances and if there was any 
effect on length of stay (LoS) of those patients who were 
readmitted following CwP referral, as well as assessing if 
the intervention had a greater effect for those patients taking 
multiple medications.
Ethics approval
Ethics approval was granted by the Chair of the Biomedical, 
Natural, Physical and Health Sciences Research Ethics Panel 
at the University of Bradford on the 8th November 2017.
Method
LTHT Medicines Management and Pharmacy Services pur-
chased the PharmOutcomes® software. Information tech-
nology support was provided to implement the system and 
with any issues encountered, as well as liaising with LTHT 
Information Governance team to ensure processes met 
appropriate standards. An implementation team was set up 
by a Consultant Pharmacist (HS). The implementation team 
was instrumental in making sure that the project worked 
in practice, engaging with staff and regularly feeding back 
issues that could be resolved. Community Pharmacy West 
Yorkshire implemented the project in community pharma-
cies in Leeds and was responsible for providing training and 
feedback.
The CwP intervention process began at the point of 
admission to hospital and was carried out by a trained hos-
pital pharmacy staff member. Information resources were 
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developed to ensure that patients were fully informed about 
CwP and the benefits. This included a patient information 
leaflet and a web-page. Patients were asked for verbal con-
sent before the CwP intervention took place. If the patient 
consented, or if the pharmacy staff member thought it was in 
their best interest (if the patient lacked capacity), the patient 
was registered on PharmOutcomes® and the community 
pharmacy would be notified of the patient’s admission to 
hospital. At the point of discharge, hospital pharmacy staff 
completed the CwP discharge information, including details 
of onward support required, and a copy of the discharge 
note was sent securely to the patient’s chosen community 
pharmacy.
Community pharmacies received a notification for each 
discharge note received from the hospital and were presented 
with a choice of either ‘accepting’ or rejecting’ it. If the 
community pharmacy did not acknowledge the referral in 
PharmOutcomes®, or did not carry out any action follow-
ing receipt, the status of that referral remained recorded as 
‘referred’, indicating no action had been taken. Data regard-
ing community pharmacy activity was captured through 
PharmOutcomes®.
The present study adopted a retrospective quasi-experi-
mental repeated measures design, in which all admissions 
pre-intervention were compared with admissions post-inter-
vention in the same sample. There was no randomisation as 
no independent control arm was included. For patients that 
received the intervention during the 3-month period January 
to April 2017 (inclusive) hospital information was extracted 
to allow the identification of total admissions 6 months pre- 
and post-intervention. Extracted data included the patient’s 
age, gender, number of medicines at discharge, number of 
ED attendances and ED length of visit (hours) as well as 
ward admissions and average LoS (days). Elective admis-
sions were excluded from analysis. If a patient was first 
assessed in ED and then transferred to a ward, this counted 
as a ward admission only. Before analysis, anomalies such as 
duplicated patient datasets or incomplete datasets, patients 
still in hospital at the end of the evaluation period and 
patient deaths during the 6-month post-intervention evalua-
tion period were removed.
The primary outcome measure was the total rate of read-
mission for all patients pre- and post-intervention. The sec-
ondary outcome measure was the total average LoS on the 
ward for all patients pre- and post-intervention. Means and 
95% Confidence Intervals were calculated. For inferential 
analysis, because the data were not normally distributed 
(assessed using Shapiro–Wilk’s Test p values < 0.05 & 
inspection of QQ-Plots) and this was a repeated measures 
design, Wilcoxon Signed-Rank Test (W) was used to exam-
ine whether there were any statistically reliable differences 
in the population pre- and post-intervention (627 pairs). Fol-
lowing visual inspection of the data using histogram plots of 
the frequency distributions, further analyses were performed 
to examine the effect of the intervention on the proportion of 
single count readmissions and three day stays.
Subset analyses of the primary and secondary outcome 
measures focused on the impact of polypharmacy and read-
mission rates. Since this variable was also not normally 
distributed, Spearman’s rank correlation coefficient (ρ) was 
computed. Subsequently, patients were divided into high and 
low polypharmacy depending on whether they had more or 
less than 10 medications at discharge and analysed for pre-
and post-intervention admission rates. This classification 
was based on previous literature identifying patients on  more 
than 10 medications being strongly associated with adverse 
drug events [28, 29]. In this case, a non-parametric aligned 
ranked test (for a two-way factorial design) was performed 
to examine whether there was an interaction between the 
intervention and polypharmacy. The threshold for statistical 
significance across all tests was set at p < 0.05. Following 
data linkage using Microsoft Excel, all preprocessing steps 
were carried out using the statistical computing environment 
R v3.4.1 [30].
Results
A total of 997 patients gave consent for their information 
to be electronically transferred to their chosen community 
pharmacy using the CwP intervention during the study 
period. The focus of this evaluation was the older patient 
population and, therefore, all patients  under 65 years were 
removed from the cohort (n = 149). Referrals that were not 
“completed” or not “actioned” (n = 22) or were deemed 
“unclaimable” or “rejected” in PharmOutcomes® (n = 38) 
were also excluded from analysis (see Fig. 1).
The mean age of the final sample was 81.69  years 
(SD = 7.4 years). Of the referrals made by LTHT, 84% were 
marked as ‘completed’ by community pharmacies, thus the 
data examined from the extraction is likely to be a repre-
sentative reflection of the intervention.
For the primary outcome measure, there was an over-
all reduction in the frequency of the total number of read-
missions post-intervention (n = 690; Mean = 1.1, 95% CI 
[0.98, 1.22]) relative to admissions prior to the interven-
tion (n = 823; Mean = 1.31, 95% CI [1.21, 1.42]) across all 
patients in the sample and this difference was statistically 
significant (W = 54,725; p < 0.0001; 200 ties). Visual inspec-
tion of the data indicated that the primary impact of the 
intervention was mediated by increasing the number of zero 
admissions (see Fig. 2). An overall 16% (n = 133) reduction 
in readmission was observed.
To explore this more formally, a contingency table with 
the number of readmissions equal to or more than one was 
constructed along with the number of zero readmissions 
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post-intervention (see Table 1). Table 1 shows the change 
in readmissions post-intervention. Here the largest improve-
ments were seen in admission avoidance with the interven-
tion: from the 627 being tracked, 193 had no admissions pre-
intervention. Post-intervention, this proportion had increased 
to 293 patients (a change of 15.95%). Modest improvements 
were seen in reducing one or more readmissions 6-months 
post-intervention (from 220 patient pre-referrals to 163; a 
9% reduction).
For the secondary outcome measure of LoS on the 
ward, there was a small mean increase post-intervention 
(Mean = 7.82, 95% CI [6.64, 9.00]) relative to pre-inter-
vention (Mean = 7.40, 95% CI [6.51, 8.29]), but this dif-
ference did not reach the statistical significance threshold 
(W = 63,462, p = 0.12; 142 ties). However, an examination 
of the frequency distribution revealed a similar pattern of 
results to the primary outcome measure; i.e. any intervention 
effect was likely to have disproportionately affected those on 
one tail of the distribution and this effect seemed to be most 
pronounced in length of ward stays of more than three days 
(see Fig. 3).
A contingency table was constructed to explore the fre-
quency of LoS duration of ≤ 3 and > 3 days (see Table 2). 
Statistical analyses revealed that there was a significant dif-
ference in the frequency count data (McNemar’s χ2 = 13.37, 
df = 1, p < 0.001). In other words, the results suggest that 
the number of patients spending more than three days in 
hospital was reduced post-intervention. This was reflected 
Fig. 1  Flow chart detailing the 
pre-processing steps involved 
in obtaining the final sample 
(n = 627) used for statistical 
analysis from the original data-
set comprising 997 patients
Fig. 2  Frequency distribution of 
the number of total emergency 
admissions pre-intervention 
(6 months) (Panel A; light blue) 
and post-intervention (Panel B; 
dark blue)
Table 1  Proportion of patient 
readmission rates ≤ 1 & > 1 
pre-and post-intervention for the 
total sample (n = 627)
Pre-referral admission 
rates
Post-referral readmis-
sion rates
Change
No readmission 193 (30.78%) 293 (46.73%)  + 100 ( + 15.95%)
Re-admissions equal to 1 220 (35.08%) 163 (26.00%) − 57 (− 9.00%)
Re-admissions greater than 1 214 (34.13%) 171 (27.27%) − 43 (− 6.86%)
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in the fact that out of the 627 patients in our sample, pre-
intervention, 237 (52.15%) of the patients spent three days 
or fewer in hospital, whilst 300 spent greater than three days. 
After the intervention, the proportion of patients spending 
three or fewer days in hospital increased to 388 patients, 
with 239 patients spending greater than three days in hospi-
tal (a change of 61 patients and shift of 9.73%).
Next, we identified whether the intervention had an asym-
metric effect depending on polypharmacy. Preliminary 
analyses showed a small positive correlation between the 
number of medications at discharge and the total number of 
interventions made across the periods examined (ρ = 0.19, 
p < 0.0001; see Fig. 4).
To explore the relationship between the interven-
tion and polypharmacy (mean number of medications at 
discharge = 11.97, SD = 4.56) data on the primary outcome 
measure (admissions frequency) was separated based on 
patients classified as “high” ( > 10 medications on refer-
ral) and “low” (< 10 medications on referral) polyphar-
macy. The difference between number of readmissions 
pre-and post-intervention tended towards statistical sig-
nificance in the high polypharmacy group (pre-interven-
tion Mean = 1.4, 95% CI [1.26, 1.55]; post-intervention 
Mean = 1.25, 95% CI [1.09, 1.41]; p = 0.066), and was 
statistically significant in the low polypharmacy group 
(pre-intervention Mean = 1.18, 95% CI [1.03, 1.33]; post-
intervention Mean = 0.87, 95% CI [0.71, 1.03]; p < 0.001). 
A non-parametric aligned ranked test (for a two-way facto-
rial design) was calculated to explore whether the impact 
of the intervention was greater in the high polypharmacy 
or low polypharmacy group, but this test revealed no inter-
action (p = 0.25).
Fig. 3  Frequency distribution 
of the total length of stay on the 
ward at LTHT pre- (6 months) 
(Panel A) and post-intervention 
(Panel B)
Table 2  Contingency Table 
showing the proportion of 
LoS ≤ 3 & > 3 days pre-and 
post-intervention
Pre-intervention LoS (%) Post-intervention 
LoS (%)
Change
Less than or equal to 3 327 (52.15%) 388 (61.88%)  + 61 (9.73%)
Greater than 3 300 (47.85%) 239 (38.12%) − 61 (− 9.73%)
Fig. 4  Positive correla-
tion between the number of 
medications at discharge and 
the total number of admissions 
across pre- and post- interven-
tion monitoring periods. Each 
coloured circle represents an 
individual patient. The dark 
grey line indicates best fit and 
the shaded region around the 
regression line is the 95% CI
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Discussion
This study evaluated the impact of introducing electronic 
transfer of a patient’s discharge information to their com-
munity pharmacy. The results demonstrated an overall 
reduction in readmissions after the introduction of the 
CwP intervention for older people. Subsidiary analyses 
revealed this effect was most pronounced in preventing 
readmissions, suggesting this as a potential tool to avoid 
hospital admissions that may result from post-discharge 
medication-related problems. Analysis of secondary 
outcomes revealed that, although there was a trend in a 
positive direction, there was no statistically reliable reduc-
tion in LoS. However, a deeper examination of the data 
revealed that the intervention seemed to impact on those 
admissions longer than three days. A similar study [24] 
with a larger sample size also found significant reduction 
in LoS for patients readmitted post-intervention, suggest-
ing that the electronic transfer of information interventions 
may have an impact on LoS. Unfortunately, the reason for 
readmission was not investigated during the data extrac-
tion so these findings must be interpreted with caution. If 
information detailing the cause of readmission was avail-
able, the effect of discrepancies in medicines reconcili-
ation, adverse drug events and other medication-related 
events on readmission could be sought.
At the outset, it was reasoned that individuals with com-
plex care needs frequently require care in different settings 
and are particularly vulnerable to experiencing medication 
problems at each care transition. This vulnerability is further 
heightened by burden of illness and accompanying polyp-
harmacy [31]. Older people are more likely to experience 
medication discrepancies after making the transition from 
hospital to home [11] due to their complex health and social 
care needs and polypharmacy [32], and therefore have the 
greatest capacity to benefit from interventions such as CwP.
Recent examination of the literature indicates there is 
no widely agreed definition for the term polypharmacy. 
The figure chosen in this study was adopted because tak-
ing more than 10 medications has been associated with the 
greatest risk of adverse drug events [28]. Interestingly in 
this study, the mean number of medications was 11.97 and 
the median was calculated to be 11. Although there was 
no reduction in readmission post-intervention in our high 
polypharmacy set, our sample was not geared towards find-
ing an effect in polypharmacy. Our next step would be to 
assess whether a follow up, and what type (such as medi-
cation review, provision of advice, medication reconcili-
ation), in such population by the community pharmacist 
has a significant impact on readmissions.
There are some limitations of this evaluation which 
would need to be addressed by future work. This study 
was not a randomised control trial, and, as such, there was 
no independent arm. Here, all participant pre-intervention 
data were retrospectively gathered to use as a baseline 
measure and compared against the same set of patients 
post-intervention. There are of course several advantages 
to this quasi-experimental approach e.g. patient demo-
graphics are carefully controlled. However, the repeated 
measures nature also means that the data collected may 
have been biased by order and time-related effects, hav-
ing an impact on the internal validity of the study. This 
makes it difficult to determine whether the CwP interven-
tion was the cause of the reduction in readmissions, or if 
these patients were likely to have reduced readmissions 
irrespective of the CwP intervention.
It is also important to consider the extent to which the 
reported results are generalisable to other settings and 
patient groups. This phase of the CwP intervention only 
included patients with a compliance aid and as such, it is 
possible that the positive effects observed here may be 
due to the specific patient characteristics of this demo-
graphic. Furthermore, 141 patients died during the fol-
low-up period and although these patients were excluded 
from all steps in the analyses, the intervention may only 
be appropriate for those at the healthier end of the spec-
trum. Whether the intervention is also efficacious for older 
patients with extremely severe health needs, along with 
those who do not use these aids remains to be seen. We 
note that in our analyses, we probed whether a proxy of 
condition complexity (i.e. polypharmacy status) could 
modulate readmission rates. We did not find an interac-
tion, tentatively suggesting that the effect is not restricted 
to complex care needs, but further research directly testing 
this hypothesis on different populations is recommended.
Whilst these results should be treated with a degree of 
caution given some of the limitations described above, the 
present analysis indicates that CwP has the potential to 
improve outcomes for older people and reduce the burden 
on hospital services by reducing the number of hospital 
readmissions and relatedly, the number of people who 
spend more than three days on the wards. Each non-elec-
tive admission is estimated to cost NHS hospitals £1,590 
whilst an excess bed day in a hospital costs approximately 
£313 per day [33]. Even modest reductions, when scaled 
across the NHS could have a substantial economic impact. 
To provide a rudimentary analysis, in the sample analysed, 
prior to the intervention, there were a total of 823 admis-
sions and post-intervention, there were 690 admissions. 
Whilst the 133 fewer admissions are unlikely to all be due 
to the CwP intervention reported here and a full evaluation 
of the economic benefit of the intervention is beyond the 
remit of this study, it can be estimated that £211,470 was 
saved in this sample post-intervention. Future, rigorous 
health economics research is necessary to determine the 
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cost-savings of CwP to explore the case for its economic 
viability.
Conclusion
The “Connect with Pharmacy” intervention recently adopted 
by Leeds Teaching Hospitals NHS Trust shows promising 
evidence, indicating that sharing discharge information with 
community pharmacies can have a positive impact on older 
patients’ transfer of care.
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